Please login to the form below

Not currently logged in
Email:
Password:

cancer drug

This page shows the latest cancer drug news and features for those working in and with pharma, biotech and healthcare.

Almirall and Evotec team up in multi-target dermatology alliance

Almirall and Evotec team up in multi-target dermatology alliance

The companies will focus on developing novel therapies for chronic skin diseases and skin cancer. ... Evotec will oversee drug discovery and pre-clinical development, while Almirall will lead the clinical development and marketing.

Latest news

More from news
Approximately 10 fully matching, plus 1,230 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 48 partially matching documents found.

Latest appointments

  • Dendreon appoints new R&D lead Dendreon appoints new R&D lead

    stage prostate cancer, with the hope of curing more men of the disease.”. ... Joining from Astellas Pharma, Dr Brown most recently served as senior medical director of oncology, where he led US medical strategy for the prostate cancer drug Xtandi

  • Storm Therapeutics strengthens its board Storm Therapeutics strengthens its board

    Paul brings a wealth of experience in cancer biology and drug discovery, in addition to the translational expertise of moving emerging biology to therapeutic applications through his experience of leading a ... world class cancer institute and being a

  • Incanthera appoints Laura Brogden as CFO Incanthera appoints Laura Brogden as CFO

    She joins from Summ.it. Drug development and targeted cancer medicines group Incanthera has appointed Laura Brogden as its new chief financial officer.

  • Former Novartis exec joins Genmab Former Novartis exec joins Genmab

    cancer drug Afinitor. ... She has a strong track record and skills in cancer drug development which will further strengthen the company as we build a winning team to continue our success in the future

  • Iris Pauporté joins OSE Immunotherapeutics Iris Pauporté joins OSE Immunotherapeutics

    Pauporté will lead the clinical development of the firm's lung cancer candidate Tedopi, which is currently in phase III trials, and will be responsible for exploring the drug's potential ... She brings over 20 years of biomedical and clinical research

More from appointments
Approximately 0 fully matching, plus 25 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Five big changes in the healthcare comms landscape
The world of healthcare has changed very greatly in the five years since The Difference Collective launched. Our agile model and talented team have enabled us to keep pace with...
Early communications in Pharma: How effective pre-approval comms delivers launch success
What communications are required for a successful launch...
Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....